Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Sumitomo Dainippon Pharma Oncology, Inc. announced that the first patient has been dosed in the Phase I dose expansion portion of the study evaluating the investigational agent TP-1287, an oral cyclin-dependent kinase 9 inhibitor, in patients with sarcoma.